Loading stock data…
$22.85+0.35 (+1.56%)
Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. in the Healthcare sector is trading at $23.02 with a market capitalization of $1.5B. Wall Street consensus targets $46.46 (13 analysts), implying a +101.8% move over the next 12 months. The stock is currently near its 52-week low of $20.32, remaining 26.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.32M↑ | $6.23M↑ | $1.40M↓ | $10.63M↓ | $13.82M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$65.43M↓ | -$53.42M↑ | -$61.44M↓ | -$43.09M↓ | -$27.30M |
| Net Income | -$61.62M↓ | -$50.00M↑ | -$57.93M↓ | -$38.35M↓ | -$23.48M |
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisen...